Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Core Insights - Anavex Life Sciences Corp. announced positive topline results from its Phase 2 clinical study of ANAVEX®3-71 for treating schizophrenia, achieving its primary endpoint of safety and tolerability in adults on stable antipsychotic medication [2][3][9] Study Results - The study demonstrated that ANAVEX®3-71 was safe and well-tolerated, with no serious treatment-emergent adverse events (TEAEs) reported [3][4] - Secondary analyses revealed encouraging trends in biomarkers, including positive trends in electroencephalography (EEG) and event-related potential (ERP) biomarkers of schizophrenia [7][8] Adverse Events Overview - In Part A of the study, 16.7% of participants on ANAVEX®3-71 experienced treatment-emergent adverse events, while no severe TEAEs were reported [4] - In Part B, 39.3% of participants on ANAVEX®3-71 experienced treatment-emergent adverse events, with no serious TEAEs reported [5][6] Biomarker Findings - Neuroinflammatory biomarker assessments indicated a reduction in glial fibrillary acidic protein (GFAP) in participants receiving ANAVEX®3-71 compared to placebo, suggesting a potential disease-modifying effect [8] Company Perspective - Company executives expressed optimism about the study results, highlighting the potential of ANAVEX®3-71 to address unmet medical needs in schizophrenia and neurodegenerative diseases [9][11]